

ForPatients

by Roche

Stroke

A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

Trial Status
Terminated

Trial Runs In
2 Countries

Trial Identifier
NCT02928393 2015-003227-66
BP29937

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02928393 2015-003227-66 BP29937
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥40 Years & ≤ 85 Years

Healthy Volunteers
No
